Senores (SENORES) | Financial Analysis & Statements
Senores Pharmaceuticals Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.3B
Gross Profit
689.4M
52.91%
Operating Income
281.8M
21.63%
Net Income
211.8M
16.25%
EPS (Diluted)
₹4.60
Balance Sheet Metrics
Total Assets
12.3B
Total Liabilities
4.1B
Shareholders Equity
8.1B
Debt to Equity
0.51
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Senores Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 3.8B | 2.1B | 353.3M | 140.7M |
| Cost of Goods Sold | 1.9B | 1.1B | 127.7M | 80.3M |
| Gross Profit | 1.9B | 1.1B | 225.6M | 60.3M |
| Gross Margin % | 50.4% | 50.5% | 63.9% | 42.9% |
| Operating Expenses | ||||
| Research & Development | 50.6M | 40.0K | 0 | 0 |
| Selling, General & Administrative | 157.3M | 140.2M | 14.9M | 9.7M |
| Other Operating Expenses | 263.6M | 313.5M | 34.7M | 3.4M |
| Total Operating Expenses | 471.5M | 453.7M | 49.6M | 13.1M |
| Operating Income | 728.1M | 315.5M | 108.9M | 12.5M |
| Operating Margin % | 19.0% | 14.7% | 30.8% | 8.9% |
| Non-Operating Items | ||||
| Interest Income | 71.6M | 4.6M | 390.0K | 1.9M |
| Interest Expense | 203.7M | 94.5M | 18.4M | 5.1M |
| Other Non-Operating Income | - | - | - | - |
| Pre-tax Income | 705.7M | 249.4M | 124.4M | 11.4M |
| Income Tax | 122.3M | -77.6M | 40.0M | 1.5M |
| Effective Tax Rate % | 17.3% | -31.1% | 32.2% | 13.3% |
| Net Income | 583.4M | 327.1M | 84.3M | 9.9M |
| Net Margin % | 15.2% | 15.2% | 23.9% | 7.0% |
| Key Metrics | ||||
| EBITDA | 1.1B | 444.1M | 160.6M | 23.6M |
| EPS (Basic) | ₹16.12 | ₹6.83 | ₹1.83 | ₹0.22 |
| EPS (Diluted) | ₹16.12 | ₹6.83 | ₹1.83 | ₹0.22 |
| Basic Shares Outstanding | 36367126 | 46053588 | 46053588 | 46053588 |
| Diluted Shares Outstanding | 36367126 | 46053588 | 46053588 | 46053588 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Senores Balance Sheet From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & Equivalents | 1.1B | 76.5M | 1.0M | 20.2M |
| Short-term Investments | 2.8B | 52.1M | - | 12.0M |
| Accounts Receivable | 1.2B | 1.1B | 221.1M | 196.3M |
| Inventory | 566.3M | 373.7M | 31.2M | 29.8M |
| Other Current Assets | 394.5M | - | - | - |
| Total Current Assets | 7.2B | 2.5B | 513.4M | 270.5M |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 64.0M | 2.0M | 1.7M | 0 |
| Goodwill | 2.6B | 1.9B | 464.4M | 88.4M |
| Intangible Assets | 1.8B | 1.2B | 464.4M | 88.4M |
| Long-term Investments | - | - | - | - |
| Other Non-Current Assets | 100.0K | - | 10.0K | 20.0K |
| Total Non-Current Assets | 5.0B | 3.7B | 797.2M | 321.0M |
| Total Assets | 12.3B | 6.2B | 1.3B | 591.5M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | 672.2M | 1.1B | 135.8M | 71.4M |
| Short-term Debt | 1.4B | 1.2B | 312.8M | 21.3M |
| Current Portion of Long-term Debt | - | - | - | - |
| Other Current Liabilities | 100.0K | - | - | - |
| Total Current Liabilities | 2.4B | 2.5B | 518.8M | 98.8M |
| Non-Current Liabilities | ||||
| Long-term Debt | 1.7B | 1.4B | 313.2M | 126.2M |
| Deferred Tax Liabilities | 0 | 0 | 21.0M | 0 |
| Other Non-Current Liabilities | -100.0K | - | - | - |
| Total Non-Current Liabilities | 1.7B | 1.4B | 336.7M | 126.8M |
| Total Liabilities | 4.1B | 3.9B | 855.5M | 225.6M |
| Equity | ||||
| Common Stock | 460.5M | 305.0M | 98.2M | 87.4M |
| Retained Earnings | 899.1M | 415.7M | 101.1M | 16.8M |
| Treasury Stock | - | - | - | - |
| Other Equity | - | - | - | - |
| Total Shareholders Equity | 8.1B | 2.3B | 455.0M | 365.9M |
| Key Metrics | ||||
| Total Debt | 3.1B | 2.6B | 625.9M | 147.6M |
| Working Capital | 4.8B | 34.1M | -5.5M | 171.7M |
Balance Sheet Composition
Senores Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | 705.7M | 249.4M | 124.4M | 11.4M |
| Depreciation & Amortization | - | - | - | - |
| Stock-Based Compensation | - | - | - | - |
| Working Capital Changes | -909.5M | -1.2B | -228.0M | -196.3M |
| Operating Cash Flow | -71.8M | -846.1M | -85.6M | -181.7M |
| Investing Activities | ||||
| Capital Expenditures | -1.6B | -518.3M | -472.8M | -106.8M |
| Acquisitions | -36.9M | -32.9M | -10.5M | -139.5M |
| Investment Purchases | - | - | - | - |
| Investment Sales | - | - | - | - |
| Investing Cash Flow | -1.6B | -551.1M | -483.3M | -246.3M |
| Financing Activities | ||||
| Share Repurchases | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Debt Issuance | - | - | - | - |
| Debt Repayment | - | - | - | - |
| Financing Cash Flow | 5.6B | 936.8M | 305.4M | 280.7M |
| Free Cash Flow | -2.0B | -775.3M | -483.6M | -211.3M |
| Net Change in Cash | 4.0B | -460.4M | -263.5M | -147.3M |
Cash Flow Trend
Senores Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
35.50
Forward P/E
29.38
Price to Book
5.54
Price to Sales
7.59
PEG Ratio
0.80
Profitability Ratios
Profit Margin
18.36%
Operating Margin
27.99%
Return on Equity
7.21%
Return on Assets
4.77%
Financial Health
Current Ratio
2.39
Debt to Equity
28.90
Per Share Data
EPS (TTM)
₹25.68
Book Value per Share
₹164.41
Revenue per Share
₹122.20
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SENORES | 41.0B | 35.50 | 5.54 | 7.21% | 18.36% | 28.90 |
| GlaxoSmithKline | 422.7B | 41.55 | 24.80 | 47.54% | 26.86% | 2.09 |
| Pfizer | 218.8B | 25.56 | 5.66 | 18.20% | 34.39% | 2.33 |
| Sms Pharmaceuticals | 37.2B | 41.86 | 5.14 | 10.81% | 9.99% | 44.47 |
| NGL Fine-Chem | 13.8B | 38.56 | 4.57 | 7.48% | 7.92% | 29.38 |
| TTK Healthcare | 13.0B | 21.64 | 1.20 | 7.67% | 7.24% | 2.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.





